284 related articles for article (PubMed ID: 33610215)
1. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.
Adamson D; Byrne A; Porter C; Blazeby J; Griffiths G; Nelson A; Sewell B; Jones M; Svobodova M; Fitzsimmons D; Nixon L; Fitzgibbon J; Thomas S; Millin A; Crosby T; Staffurth J; Hurt C
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):292-303. PubMed ID: 33610215
[TBL] [Abstract][Full Text] [Related]
2. Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT.
Adamson D; Blazeby J; Porter C; Hurt C; Griffiths G; Nelson A; Sewell B; Jones M; Svobodova M; Fitzsimmons D; Nixon L; Fitzgibbon J; Thomas S; Millin A; Crosby T; Staffurth J; Byrne A
Health Technol Assess; 2021 May; 25(31):1-144. PubMed ID: 34042566
[TBL] [Abstract][Full Text] [Related]
3. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial.
Adamson D; Blazeby J; Nelson A; Hurt C; Nixon L; Fitzgibbon J; Crosby T; Staffurth J; Evans M; Kelly NH; Cohen D; Griffiths G; Byrne A
Trials; 2014 Oct; 15():402. PubMed ID: 25336193
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Crosby T; Hurt CN; Falk S; Gollins S; Mukherjee S; Staffurth J; Ray R; Bashir N; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G
Lancet Oncol; 2013 Jun; 14(7):627-37. PubMed ID: 23623280
[TBL] [Abstract][Full Text] [Related]
5. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).
Penniment MG; De Ieso PB; Harvey JA; Stephens S; Au HJ; O'Callaghan CJ; Kneebone A; Ngan SY; Ward IG; Roy R; Smith JG; Nijjar T; Biagi JJ; Mulroy LA; Wong R;
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):114-124. PubMed ID: 29248399
[TBL] [Abstract][Full Text] [Related]
6. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer.
Shenfine J; McNamee P; Steen N; Bond J; Griffin SM
Health Technol Assess; 2005 Feb; 9(5):iii, 1-121. PubMed ID: 15717937
[TBL] [Abstract][Full Text] [Related]
7. Interventions for dysphagia in oesophageal cancer.
Dai Y; Li C; Xie Y; Liu X; Zhang J; Zhou J; Pan X; Yang S
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005048. PubMed ID: 25354795
[TBL] [Abstract][Full Text] [Related]
8. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial.
Javed A; Pal S; Dash NR; Ahuja V; Mohanti BK; Vishnubhatla S; Sahni P; Chattopadhyay TK
J Gastrointest Cancer; 2012 Mar; 43(1):63-9. PubMed ID: 20835926
[TBL] [Abstract][Full Text] [Related]
9. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
10. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
11. Outcome of palliative esophageal stenting for malignant dysphagia: a retrospective analysis.
Burstow M; Kelly T; Panchani S; Khan IM; Meek D; Memon B; Memon MA
Dis Esophagus; 2009; 22(6):519-25. PubMed ID: 19302213
[TBL] [Abstract][Full Text] [Related]
12. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham D; Stenning SP; Smyth EC; Okines AF; Allum WH; Rowley S; Stevenson L; Grabsch HI; Alderson D; Crosby T; Griffin SM; Mansoor W; Coxon FY; Falk SJ; Darby S; Sumpter KA; Blazeby JM; Langley RE
Lancet Oncol; 2017 Mar; 18(3):357-370. PubMed ID: 28163000
[TBL] [Abstract][Full Text] [Related]
13. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
14. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial.
Zhu HD; Guo JH; Mao AW; Lv WF; Ji JS; Wang WH; Lv B; Yang RM; Wu W; Ni CF; Min J; Zhu GY; Chen L; Zhu ML; Dai ZY; Liu PF; Gu JP; Ren WX; Shi RH; Xu GF; He SC; Deng G; Teng GJ
Lancet Oncol; 2014 May; 15(6):612-9. PubMed ID: 24742740
[TBL] [Abstract][Full Text] [Related]
15. WITHDRAWN: Interventions for dysphagia in oesophageal cancer.
Sreedharan A; Harris K; Crellin A; Forman D; Everett SM
Cochrane Database Syst Rev; 2011 Feb; (2):CD005048. PubMed ID: 21328271
[TBL] [Abstract][Full Text] [Related]
16. Interventions for dysphagia in oesophageal cancer.
Sreedharan A; Harris K; Crellin A; Forman D; Everett SM
Cochrane Database Syst Rev; 2009 Oct; (4):CD005048. PubMed ID: 19821338
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Kitchener HC; Nijman HW; Kruitwagen RF; Nout RA; Verhoeven-Adema KW; Smit VT; Putter H; Creutzberg CL;
Lancet Oncol; 2016 Aug; 17(8):1114-1126. PubMed ID: 27397040
[TBL] [Abstract][Full Text] [Related]
18. Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: impact on quality of life.
Madhusudhan C; Saluja SS; Pal S; Ahuja V; Saran P; Dash NR; Sahni P; Chattopadhyay TK
Dis Esophagus; 2009; 22(4):331-6. PubMed ID: 19473211
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Alderson D; Cunningham D; Nankivell M; Blazeby JM; Griffin SM; Crellin A; Grabsch HI; Langer R; Pritchard S; Okines A; Krysztopik R; Coxon F; Thompson J; Falk S; Robb C; Stenning S; Langley RE
Lancet Oncol; 2017 Sep; 18(9):1249-1260. PubMed ID: 28784312
[TBL] [Abstract][Full Text] [Related]
20. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).
Vaidya JS; Wenz F; Bulsara M; Tobias JS; Joseph DJ; Saunders C; Brew-Graves C; Potyka I; Morris S; Vaidya HJ; Williams NR; Baum M
Health Technol Assess; 2016 Sep; 20(73):1-188. PubMed ID: 27689969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
